PROTEOMICS INTERNATIONAL LABORATORIES LTD

Proteomics International Laboratories Ltd

PIQ

AU000000PIQ0

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 07:10:22 23/05/2024 BST			5-day change	1st Jan Change
0.99 ^AUD	+0.51%		-5.71%	+10.61%

05-16	Proteomics International Laboratories Supports Root Rot Study with Biomarker Platform	MT
03-25	Proteomics International Signs Agreement with University of Oxford for Endometriosis Study	MT

Proteomics International Laboratories Ltd Announces Cessation of James Owen Moses as Director

June 30, 2016 at 02:53 am

Proteomics International Laboratories Ltd. announced that the cessation of James Owen Moses as director, effective 30 June 2016.

Latest news about Proteomics International Laboratories Ltd

Proteomics International Laboratories Supports Root Rot Study with Biomarker Platform	05-16	MT
Proteomics International Signs Agreement with University of Oxford for Endometriosis Study	03-24	MT
Proteomics Says PromarkerD's US Launch Delayed	03-19	MT
Proteomics International Laboratories Secures ISO 13485 Certification Renewal	03-06	MT
Proteomics International Laboratories Narrows Fiscal H1 Loss	02-23	MT
Proteomics International Laboratories Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-23	CI
Proteomics International's Blood Test for Uterine Disease Undergoes Biomarker Validation	02-01	MT
Proteomics International's Blood Test for Throat Cancer Undergoes Biomarker Validation	02-01	MT
Proteomics International Laboratories Raises AU$6.5 Million for Test Commercialization, Further Development; Shares Down 10%	01-23	MT
Proteomics Signs Deal to Sell PromarkerD in Chile; Shares Jump 5%	12-20	MT
Proteomics International Laboratories Receives More than AU$1.8 Million R&D Tax Rebate	11-09	MT
Proteomics International Laboratories Requests Extension of Securities Trading Suspension	20/09/23	MT
Proteomics International Subsidiary Secures New Patent in Japan; Shares Fall 4%	04/09/23	MT
Proteomics International Laboratories Limited Reports Earnings Results for the Full Year Ended June 30, 2023	21/08/23	CI
Proteomics International Laboratories Signs Deal to Commercialize Diagnostic Test in the US; Shares Rally 11%	10/05/23	MT
Proteomics International Laboratories Renews ISO 13485 Certification, ISO 17025 Accreditation	17/04/23	MT
Proteomics International Laboratories Verifies Effectivity of Endometriosis Diagnostic Test	24/03/23	MT
Proteomics International Laboratories to Resubmit Medicare Application for Diagnostic Test in Australia	15/03/23	MT
Proteomics International Laboratories Limited Announces to Resubmit Application for PromarkerD Listing on Australian Medicare Benefits Schedule	15/03/23	CI
Proteomics International Laboratories Limited Provides Update on Exclusive Licence Agreement with Sonic Healthcare USA, Inc	28/02/23	CI
Proteomics International Laboratories Limited Reports Earnings Results for the Half Year Ended December 31, 2022	27/02/23	CI
Proteomics International Laboratories Extends Predictive Test Distribution Agreement in Britain	15/02/23	MT
Proteomics International Laboratories Ltd Extends its Distribution Agreement with Apacor Limited to Bring its PromarkerD Predictive Test for Diabetic Kidney Disease to Patients in England, Scotland and Wales	14/02/23	CI
Proteomics International Laboratories Limited Announces Letter of Intent with Sonic Healthcare USA Extended	30/01/23	CI
Proteomics International Laboratories Raises AU$1.8 Million from Options Exercise	27/01/23	MT

Chart Proteomics International Laboratories Ltd

Duration

Period

Chart Proteomics International Laboratories Ltd

More charts

Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bio-analytical services. The Company specializes in proteomics, the study of the structure and function of proteins. The Company focuses on developing and commercializing diagnostic tests for chronic diseases. The Company operates in three business units unified by a technology platform: PromarkerD, Diagnostics and Analytical Services. The PromarkerD test system is a blood test that assess the risk of diabetic kidney disease (DKD) in patients with type 2 diabetes. Diagnostics includes Promarker platform, used to discover, verify, and analytically validate the panel of protein biomarkers for diabetic kidney disease. Its Analytical Services includes a proteomics-based technology platform, used to test, and validate the protein composition of varied range of products.

Sector

Biotechnology & Medical Research

Calendar

27/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Proteomics International Laboratories Ltd

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.985 AUD

Average target price

1.38 AUD

Spread / Average Target

+40.10%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PROTEOMICS INTERNATIONAL LABORATORIES LTD	+10.61%	85.6M
VERTEX PHARMACEUTICALS INCORPORATED	+11.04%	115B
REGENERON PHARMACEUTICALS, INC.	+12.46%	106B
BIONTECH SE	-4.16%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-13.10%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+6.29%	14.03B
SAREPTA THERAPEUTICS, INC.	+31.61%	12.13B

Bio Therapeutic Drugs